ClinicalTrials.gg
CompletedNCT04928703Updated Feb 21, 2023

Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

An Early Phase 1 interventional study of Ketamine in Healthy, sponsored by ERP Biomarker Qualification Consortium. Completed at 1 site in United States. Open to participants aged 21 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by ERP Biomarker Qualification Consortium · Early Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
21 Years to 40 Years
Sex
All
01

Study summary

This is a Phase 0, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to assess the changes in ERP Biomarkers in Healthy Volunteers before and after administration of a sub-anesthetic dose of ketamine. Primary objectives are to quantify the effect size of ketamine-induced changes on MMN from a duration-deviant auditory oddball ERP test and to quantify the variability of ketamine-induced changes on MMN from a duration-deviant auditory oddball ERP test.

Read the detailed description

The effects of ketamine and similar compounds on brain function have become of significant interest to pharma companies in the past few years. These effects are often used as a model for the glutamatergic hypofunction hypothesis of schizophrenia and therefore drugs targeting schizophrenia are being trialed to reverse or block the effects of ketamine. Esketamine has been recently approved as a potent treatment for depression so many pharma companies are trying to leverage ketamine-like modulation of the NMDA receptors as novel targets for depression.

This heightened focus on NMDAr modulators has lead industry and academia to advance methods to measure these effects. Many studies have been performed using EEG and ERP techniques to measure the effect on brain function of ketamine administration but no study has been performed, to our knowledge, that has attempted to measure the variability and reproducibility of these effects. Furthermore, there is some evidence from the scientific literature and from unpublished results from industry-sponsored studies that ketamine may have a disordinal effect on various electrophysiologic measures, particularly the amplitude of the mismatch negativity (MMN) from an auditory oddball ERP test.

In this study we will run various EEG/ERP tests on participants during a placebo administration and during two ketamine administrations separated by washout periods. This will allow, for the first time, the evaluation of the test-retest variability of a range ERP/EEG measures under ketamine administration vs placebo. This may also allow us to test the hypothesis that ketamine has a disordinal effect on different subjects and this disordinality can be predicted from a baseline (placebo) measurement.

02

Conditions studied

  • Healthy

Keywords

  • Event-related potential
  • Electroencephalogram
  • ERP
  • EEG
  • Ketamine
  • Mismatch Negativity
  • MMN
  • N100
  • P3a
  • P3b
  • P300
03

In context

Lead sponsor

ERP Biomarker Qualification Consortium is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects 21-40 years of age, inclusive at Visit 1 (Screening).
  2. Female subjects with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of (e.g., oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan to become pregnant during the study and for 30 days after the last dose of ketamine.
  3. Ability to understand the requirements of the study, provide written , abide by the study restrictions, and agree to return for the required assessments.
  4. Subject is judged to be in good health as determined by the investigator.
  5. (BMI ) between 18.5 and 30.0 (inclusive) at Visit 1 (Screening).
  6. Ability to detect a 1000 and 2000 Hz tone at 40 dB in both ears, at Visit 1 (Screening).
  7. Ability to tolerate the electrode cap for the duration of the testing session.

Exclusion criteria

Exclusion Criteria:

  1. alcohol or other substance abuse within the last 1 year, in the opinion of the investigator; or unable to abstain from alcoholic beverages during the course of the study.
  2. Positive alcohol/drug screen for drugs of abuse (with the exception of a positive result considered by the investigator to be directly attributable to prescription medication approved for subject use) such as phencyclidine, benzodiazepines, opiates, cocaine, cannabinoids, amphetamines, and cotinine at any Visit.
  3. Excessive caffeine use (defined as habitual consumption of > 400 mg caffeine per day [\~ four 8 oz. cups brewed caffeinated coffee or tea, \~ ten 12 oz. cans caffeinated soda or \~ two "energy shot" drinks]), or unable to abstain from caffeine on Visits 2-4.
  4. Use of products containing nicotine (tobacco or vaping products) 60 minutes prior to dosing on Visits 2-4.
  5. Current or prior history (defined as in the past 6 months) of treatment with N-methyl-D-aspartate receptor (NMDAR) ligands including ketamine, amantadine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.
  6. History of allergy, sensitivity, or intolerance to NMDAR ligands including ketamine, amantadine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.
  7. Any impairment, activity, or situation that in the judgment of the investigator would prevent satisfactory completion of the study protocol.
  8. History of significant psychiatric, neurologic (e.g. Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, Type I or Type II diabetes mellitus, or a history of seizures, epilepsy, or strokes), or cognitive disorders (e.g. bipolar, schizophrenia, psychosis), or current (within 12 months prior to screening) psychiatric or cognitive disorders such as major depression, suicidal ideation, dementia, or anxiety disorders).
  9. Abnormal medical history, or concurrent conditions that, in the opinion of the investigator or sponsor designated medical monitor, would preclude safe study participation, or interfere with study procedures/assessments.
  10. History of severe renal or hepatic impairment, in the opinion of the investigator or the sponsor medical monitor.
  11. Known history of significant cardiovascular condition such as myocardial infarction, congestive heart failure, clinically significant arrhythmias, current uncontrolled cardiac arrhythmias, angina, acute ischemia.
  12. Hypertension characterized by resting systolic blood pressure > 140 mmHg or resting diastolic > 90 mmHg or tachycardia defined as a resting HR ≥ 120 bpm or bradycardia defined as a resting HR of ≤ 50 bpm, at any Visit.
  13. Hypotension with an abnormal supine blood pressure defined as SBP \< 90 mmHg or DBP \<60 mmHg at any Visit.
  14. Orthostatic hypotension consisting of a SBP change of ≥ 30 mmHg or a DBP change of ≥ 20 mmHg at 3 minutes after standing from a supine position at any Visit.
  15. Resting heart rate \< 45 or > 95 beats per minute.
  16. A marked baseline prolongation of /QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant finding at Visit 1 (Screening).
  17. A history of additional risk factors for Torsade de Pointes (such as heart failure, hypokalaemia, or family history of Long QT Syndrome).
  18. Current evidence of dysplasia or history of (including lymphoma and leukemia) in the last 5 years, with the exception of successfully treated non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  19. (HIV) infection, hepatitis, or other ongoing infectious disease that the investigator considers clinically significant.
  20. History of gastrointestinal disease or surgery (except simple appendectomy or hernia repair), which can influence the absorption of the study drug.
  21. Evidence of an infection at the time of clinic admission, in the opinion of the investigator.
  22. Received an product or device within 30 days (or 5 half-lives, whichever is longer) of dosing.
  23. Use of first generation, sedating H1 antihistamines or sedative-hypnotic medications within 1 week prior to dosing.
  24. Poor venous access; or have donated or had a significant loss of blood or plasma within 8 weeks of dosing.
  25. Known allergy to latex.
  26. Prior adverse reaction to ketamine or esketamine.
  27. Medical history, conditions, or situations that, in the opinion of the investigator, would preclude safe study participation, or interfere with study procedures/assessments.
  28. In addition to these criteria, the investigator may discontinue subjects at any time based on his or her clinical judgment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Arm 1

    Visit 2: Placebo - Placebo; Visit 3: Placebo - Ketamine; Visit 4: Placebo - Ketamine

    Drug: Ketamine

  • Experimental
    Arm 2

    Visit 2: Placebo - Ketamine; Visit 3: Placebo - Placebo; Visit 4: Placebo - Ketamine

    Drug: Ketamine

  • Experimental
    Arm 3

    Visit 2: Placebo - Ketamine; Visit 3: Placebo - Ketamine; Visit 4: Placebo - Placebo

    Drug: Ketamine

Interventions

06

What researchers measure

Primary outcomes

  1. Ketamine-induced changes in Amplitude for parameters from the ERP tests.

    Amplitude changes (in microvolts) for the following parameters from the ERP tests: 1. Passive, Duration-deviant, Oddball ERP a. MMN

    Time frame: Pre-intervention/Dosing

Secondary outcomes

  1. Ketamine-induced changes in Amplitude for parameters from the ERP tests.

    Amplitude changes (in microvolts) for the following parameters from the ERP tests: 1. Passive, Duration-deviant, Oddball ERP 1. N100 2. P3a 2. Active, Auditory Oddball ERP 1. N100 2. N200 3. P3b

    Time frame: Pre-intervention/Dosing

  2. Ketamine-induced changes in Latency for parameters from the ERP tests.

    Latency changes (in milliseconds) for the following parameters from the ERP tests: 1. Passive, Duration-deviant, Oddball ERP 1. N100 2. MMN 3. P3a 2. Active, Auditory Oddball ERP 1. N100 2. N200 3. P3b

    Time frame: Pre-intervention/Dosing

  3. Ketamine-induced change in Task Accuracy from the behavioral response during the active, auditory oddball ERP test.

    Change in Task Accuracy as a percentage of correct behavioral responses during the active, auditory oddball ERP test.

    Time frame: Pre-intervention/Dosing

  4. Ketamine-induced change in Reaction Time from the behavioral response during the active, auditory oddball ERP test.

    Change in Reaction Time for the correct behavioral responses measured in milliseconds during the active, auditory oddball ERP test.

    Time frame: Pre-intervention/Dosing

  5. Ketamine-induced change in Evoked Power from the auditory steady-state response (ASSR) paradigm.

    Change in Evoked Power measured in µv2/Hz from the ASSR paradigm.

    Time frame: Pre-intervention/Dosing

  6. Ketamine-induced change in Inter-trial coherence (ITC) from the auditory steady-state response (ASSR) paradigm.

    Inter-trial coherence (ITC) from the ASSR paradigm will be measured on a scale between 0 (no coherence) and 1 (maximum coherence). Outcome measure will be change in ITC.

    Time frame: Pre-intervention/Dosing

  7. Ketamine-induced changes in Absolute Power for Pharmaco-EEG parameters per IPEG guidelines.

    Changes in Absolute Power (measured in µv2/Hz) for the following Pharmaco-EEG parameters: * Delta power * Theta power * Alpha power * Beta power * Gamma power * Total power

    Time frame: Pre-intervention/Dosing

  8. Ketamine-induced changes in Relative Power for Pharmaco-EEG parameters per IPEG guidelines.

    Relative Power for Pharmaco-EEG parameters will be measured on a scale from 0 (no power in frequency band) to 1 (all EEG power in that frequency band). Outcome measures will be changes in Relative Power for the following Pharmaco-EEG parameters: * Delta power * Theta power * Alpha power * Beta power

    Time frame: Pre-intervention/Dosing

  9. Ketamine-induced change in the Dominant Frequency for the Alpha frequency band per IPEG guidelines.

    Dominant frequency will be measured in Hz in the frequency interval between 6.0 and \< 12.5 Hz. Outcome measure will be change in the Dominant Frequency for the Alpha frequency band.

    Time frame: Pre-intervention/Dosing

  10. Ketamine-induced changes in Slow Wave Index per IPEG guidelines.

    Slow Wave Index (SWI) will be calculated as Alpha/(Delta+Theta), and will be measured as ratio. Outcome measure will be change in SWI.

    Time frame: Pre-intervention/Dosing

  11. Ketamine-induced changes in Theta/Beta ratio per IPEG guidelines.

    Theta/Beta (TBR) will be measured as ratio. Outcome measure will be change in TBR.

    Time frame: Pre-intervention/Dosing

  12. Correlations between Ketamine blood concentration and Ketamine-induced changes in Amplitude for parameters from the ERP tests.

    Correlations between ketamine blood concentration and amplitude changes (in microvolts) for the following parameters from the ERP tests: 1. Passive, Duration-deviant, Oddball ERP a. MMN 2. Passive, Duration-deviant, Oddball ERP 1. N100 2. P3a 3. Active, Auditory Oddball ERP 1. N100 2. N200 3. P3b

    Time frame: Pre-intervention/Dosing

  13. Correlations between Ketamine blood concentration and Ketamine-induced changes in Latency for parameters from the ERP tests.

    Correlations between ketamine blood concentration and latency changes (in milliseconds) for the following parameters from the ERP tests: 1. Passive, Duration-deviant, Oddball ERP a. MMN 2. Passive, Duration-deviant, Oddball ERP 1. N100 2. P3a 3. Active, Auditory Oddball ERP 1. N100 2. N200 3. P3b

    Time frame: Pre-intervention/Dosing

  14. Correlation between Ketamine blood concentration and Ketamine-induced change in Task Accuracy from the behavioral response during the active, auditory oddball ERP test.

    Correlation between Ketamine blood concentration and change in Task Accuracy measured as a percentage of correct behavioral responses during the active, auditory oddball ERP test.

    Time frame: Pre-intervention/Dosing

  15. Correlation between Ketamine blood concentration and Ketamine-induced change in Reaction Time from the behavioral response during the active, auditory oddball ERP test.

    Correlation between Ketamine blood concentration and change in Reaction Time for the correct behavioral responses measured in milliseconds during the active, auditory oddball ERP test.

    Time frame: Pre-intervention/Dosing

  16. Correlation between Ketamine blood concentration and Ketamine-induced change in Evoked Power from the auditory steady-state response (ASSR) paradigm.

    Correlation between Ketamine blood concentration and change in Evoked Power measured in µv2/Hz from the ASSR paradigm.

    Time frame: Pre-intervention/Dosing

  17. Correlation between Ketamine blood concentration and Ketamine-induced change in Inter-trial coherence (ITC) from the auditory steady-state response (ASSR) paradigm.

    Correlation between Ketamine blood concentration and change in Inter-trial coherence (ITC) from the ASSR paradigm. Change in ITC will be measured on a scale between 0 (no coherence) and 1 (maximum coherence).

    Time frame: Pre-intervention/Dosing

  18. Correlation between Ketamine blood concentration and Ketamine-induced changes in Absolute Power for Pharmaco-EEG parameters.

    Correlation between Ketamine blood concentration and changes in Absolute Power (measured in µv2/Hz) for the following Pharmaco-EEG parameters: * Delta power * Theta power * Alpha power * Beta power * Gamma power * Total power

    Time frame: Pre-intervention/Dosing

  19. Correlation between Ketamine blood concentration and Ketamine-induced changes in Relative Power for Pharmaco-EEG parameters.

    Correlation between Ketamine blood concentration and changes in Relative Power for the following Pharmaco-EEG parameters: * Delta power * Theta power * Alpha power * Beta power

    Time frame: Pre-intervention/Dosing

  20. Correlation between Ketamine blood concentration and Ketamine-induced change in the Dominant Frequency for the Alpha frequency band.

    Correlation between Ketamine blood concentration and Dominant frequency for the Alpha frequency band measured in Hz in the frequency interval between 6.0 and \< 12.5 Hz.

    Time frame: Pre-intervention/Dosing

  21. Correlation between Ketamine blood concentration and Ketamine-induced changes in Slow Wave Index.

    Correlation between Ketamine blood concentration and changes Slow Wave Index (SWI) calculated as Alpha/(Delta+Theta) ratio.

    Time frame: Pre-intervention/Dosing

  22. Correlation between Ketamine blood concentration and Ketamine-induced changes in Theta/Beta ratio.

    Correlation between Ketamine blood concentration and changes in Theta/Beta ratio (TBR).

    Time frame: Pre-intervention/Dosing

07

Study locations

1 site
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Dec 2022, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 16, 2021
StartActual
May 26, 2022
Primary completionActual
Dec 12, 2022
CompletionActual
Dec 12, 2022
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04928703
Lead sponsor
ERP Biomarker Qualification Consortium
Collaborators
Alkermes, Inc., Anavex Life Sciences Corp., Astellas Pharma Inc, H. Lundbeck A/S, Merck Sharp & Dohme LLC, Novartis, Sage Therapeutics, Takeda, Apex Innovative Sciences, COGNISION
Responsible party
Sponsor
First posted
Jun 16, 2021
Start date
May 26, 2022
Primary completion
Dec 12, 2022
Completion
Dec 12, 2022
Last update
Feb 21, 2023

Study contacts

Marco Cecchi, PhD
principal investigator · The ERP Biomarker Qualification Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion